Thyroid & Nasopharyngeal Cancer | Dr. Guo Liang (Head & Neck Surgery) | CMCS Shanghai

About Dr. Guo Liang

Dr. Guo Liang is Director of Head and Neck Surgery at Fudan University Shanghai Cancer Center — China's foremost oncology institution and one of the highest-volume head and neck cancer surgical centres in the country. He is one of China's most respected head and neck oncological surgeons, recognised for his expertise in thyroid cancer surgery, nasopharyngeal carcinoma management, salivary gland tumour resection, and the multidisciplinary treatment of synchronous multiple primary malignancies of the head and neck. Dr. Guo's practice is defined by the philosophy that multiple primary malignancies are not a diagnostic curiosity — they are a clinical imperative that demands systematic evaluation of every anatomical region in a patient presenting with a head and neck tumour, because a missed synchronous primary is a missed opportunity for curative treatment. His department at Fudan University Shanghai Cancer Center has established one of China's most comprehensive head and neck oncology programmes, integrating endoscopic tumour assessment, ultrasound-guided biopsy, intensity-modulated radiotherapy, concurrent chemotherapy, precision thyroid surgery, and structured long-term surveillance into a unified care pathway for patients with complex head and neck malignancy.

Case Overview

Mr. Andrew Morrison (pseudonym), a 52-year-old Australian company executive based in Shanghai, presented with a three-month history of a left neck mass and blood-tinged nasal discharge on morning expectoration. Nasopharyngoscopy revealed a cauliflower-like lesion on the posterior nasopharyngeal wall; biopsy confirmed poorly differentiated squamous cell carcinoma. Enhanced CT demonstrated left nasopharyngeal soft tissue thickening with invasion of surrounding structures and multiple left cervical lymph nodes up to 3 cm — staged T3N1M0 per AJCC 8th edition. Thyroid ultrasound, performed as part of the systematic head and neck evaluation, identified a 1.2 cm left thyroid lobe hypoechoic nodule with irregular margins, microcalcifications, and a longitudinal-to-transverse ratio greater than 1; fine-needle aspiration biopsy confirmed papillary thyroid carcinoma, staged cT1aN0M0. A multidisciplinary team led by Dr. Guo Liang recommended sequential treatment: IMRT-based concurrent chemoradiotherapy (70 Gy in 35 fractions; weekly cisplatin 40 mg/m² for 6 cycles) for the NPC, followed three months later by left hemithyroidectomy with central neck dissection for the thyroid cancer. At three months post-chemoradiotherapy, nasopharyngeal MRI showed near-complete response of the primary tumour and cervical nodes. Thyroid surgery confirmed papillary carcinoma with clear margins and no central nodal metastasis (0/6 nodes). At three-year follow-up, both tumours remain in complete remission.

Patient Background

• Name / Nationality: Mr. Andrew Morrison (pseudonym) — Australian; 52-year-old company executive based in Shanghai
• Age / Sex: 52-year-old male
• Chief Complaint: Left neck mass for three months; blood-tinged nasal discharge on morning expectoration for three months; both symptoms worsening over the past month
• Neck mass characteristics: Left neck mass approximately pigeon-egg size at presentation; hard consistency; poorly defined margins; limited mobility; non-tender; progressive enlargement over one month
• Nasal symptoms: Blood-tinged nasal discharge on morning expectoration (回吸性血涕) — the characteristic presenting symptom of nasopharyngeal carcinoma; no nasal obstruction, tinnitus, hearing loss, or headache
• No relevant past medical history: No hypertension, diabetes, or cardiovascular disease; no hepatitis or tuberculosis; no prior surgery or trauma; no smoking or alcohol excess
• No family history of malignancy
• Examination — neck: Left neck mass 4 cm × 3 cm; hard; poorly defined; immobile; non-tender; no additional palpable cervical lymphadenopathy
• Examination — nasopharynx: Indirect and fibre-optic nasopharyngoscopy — cauliflower-like lesion on the posterior nasopharyngeal roof; irregular surface; mucosal erosion and contact bleeding
• Examination — thyroid: No palpable thyroid mass; no tenderness; normal mobility on swallowing — thyroid carcinoma identified only on systematic ultrasound evaluation

Diagnostic Workup

Nasopharyngeal Biopsy

• Technique: Endoscopy-guided biopsy of the posterior nasopharyngeal wall lesion
• Pathology: Poorly differentiated squamous cell carcinoma — the predominant histological subtype of nasopharyngeal carcinoma in endemic regions; WHO Type III (non-keratinising undifferentiated carcinoma); strongly associated with Epstein-Barr virus (EBV)

Enhanced CT (Neck and Nasopharynx)

• Primary tumour: Left nasopharyngeal soft tissue thickening with invasion of surrounding structures — T3 disease (invasion beyond the nasopharynx)
• Cervical lymph nodes: Multiple enlarged left cervical lymph nodes; maximum diameter 3 cm — N1 disease (unilateral cervical nodal involvement)
• Staging: T3N1M0 per AJCC 8th edition — locoregionally advanced NPC; no distant metastasis

Thyroid Ultrasound

• Left thyroid lobe nodule: 1.2 cm × 1.0 cm hypoechoic nodule; irregular margins; microcalcifications; longitudinal-to-transverse ratio >1 (taller-than-wide configuration) — ACR TIRADS 5 / high suspicion for malignancy
• Clinical significance: Thyroid nodule identified on systematic head and neck evaluation — not clinically apparent on palpation; demonstrates the importance of ultrasound screening of the thyroid in all head and neck cancer patients

Thyroid Fine-Needle Aspiration Biopsy (FNAB)

• Technique: Ultrasound-guided FNAB of the left thyroid lobe nodule
• Cytology: Papillary thyroid carcinoma — Bethesda Category VI (malignant); nuclear features of PTC confirmed (nuclear grooves, pseudoinclusions, ground-glass nuclei)
• Staging: cT1aN0M0 — tumour ≤1 cm, confined to the thyroid, no nodal or distant metastasis

Distant Metastasis Workup

• Whole-body bone scan, chest CT, abdominal ultrasound: No evidence of distant metastasis — M0 disease confirmed for both primary tumours

Dr. Guo's diagnostic assessment: The neck mass and the blood-tinged nasal discharge together are the classic presentation of nasopharyngeal carcinoma with cervical nodal metastasis. The nasopharyngoscopy confirmed the primary, the biopsy confirmed the histology, and the CT confirmed the nodal disease. That is the NPC diagnosis. But in every patient with a head and neck malignancy, we perform a systematic ultrasound of the thyroid — because the thyroid is in the field, and because thyroid cancer is common enough that synchronous disease is not rare. In this patient, the thyroid ultrasound found a TIRADS 5 nodule that was completely impalpable. The FNAB confirmed papillary carcinoma. Without the systematic ultrasound, that cancer would have been missed. The NPC would have been treated, the patient would have been followed for NPC recurrence, and the thyroid cancer would have grown silently. Systematic evaluation of every anatomical region is not optional in head and neck oncology — it is the standard of care.

Multidisciplinary Team Discussion and Treatment Strategy

The MDT convened by Dr. Guo Liang included head and neck surgery, medical oncology, radiation oncology, and radiology. The consensus was that both tumours required treatment, that the NPC was the immediate priority given its locoregional advancement and symptomatic burden, and that the thyroid cancer — a low-risk T1a papillary carcinoma — could safely be deferred until after NPC chemoradiotherapy without compromising the oncological outcome.

NPC treatment — concurrent chemoradiotherapy: NPC is highly radiosensitive — intensity-modulated radiotherapy (IMRT) with concurrent platinum-based chemotherapy is the international standard of care for locoregionally advanced NPC (T3N1M0). IMRT delivers conformal high-dose radiation to the nasopharyngeal primary and bilateral cervical nodal drainage regions while sparing adjacent critical structures — the parotid glands, spinal cord, brainstem, and optic apparatus. Total dose: 70 Gy in 35 fractions to the primary tumour and involved nodes; concurrent cisplatin 40 mg/m² weekly for 6 cycles as a radiosensitiser.

Thyroid cancer treatment — deferred surgery: Left hemithyroidectomy (left lobe and isthmus) with left central neck dissection, scheduled three months after completion of NPC chemoradiotherapy — allowing the patient to recover physiological reserve and for the acute radiation effects on the neck to subside before operating in the irradiated field. Post-operative TSH suppression therapy with levothyroxine.

Sequencing rationale: Treating the NPC first addresses the immediate life threat and symptomatic burden. The thyroid cancer, at cT1aN0M0, has an excellent prognosis with a 10-year disease-specific survival exceeding 99% — a three-month deferral does not meaningfully alter the oncological outcome. Operating on the thyroid during or immediately after neck irradiation would increase the risk of wound healing complications, hypoparathyroidism, and recurrent laryngeal nerve injury in an irradiated field.

Treatment Course

Stage 1 — NPC Concurrent Chemoradiotherapy (IMRT + Cisplatin)

IMRT planning: CT simulation with thermoplastic mask immobilisation; target volumes delineated by the radiation oncology team — gross tumour volume (GTV) encompassing the nasopharyngeal primary and involved cervical nodes; clinical target volumes (CTV) encompassing the nasopharynx, skull base, and bilateral cervical nodal drainage regions at risk. IMRT plan optimised to deliver 70 Gy to the GTV while constraining dose to the parotid glands (mean dose <26 Gy to preserve salivary function), spinal cord (<45 Gy), and brainstem (<54 Gy).

Concurrent chemotherapy: Cisplatin 40 mg/m² intravenously weekly for 6 cycles — administered on the same days as radiotherapy to maximise radiosensitisation. Pre-medication with antiemetics and intravenous hydration before each cisplatin infusion.

Acute toxicity management: Oral mucositis — managed with oral hygiene protocol, topical anaesthetic rinses, and analgesics; symptoms gradually resolved with supportive care. Nausea and vomiting from cisplatin — managed with 5-HT3 antagonist antiemetics; mild and well-controlled. Full course of chemoradiotherapy completed without treatment interruption.

Dr. Guo's treatment note: IMRT has transformed the treatment of nasopharyngeal carcinoma. Before IMRT, conventional radiotherapy delivered high doses to the parotid glands, causing permanent xerostomia — dry mouth — in the majority of patients. IMRT allows us to sculpt the dose distribution around the parotid glands, reducing the mean parotid dose below the threshold for permanent salivary dysfunction in most patients. The concurrent cisplatin is the radiosensitiser — it does not add much systemic antitumour activity at the weekly low dose we use, but it makes the tumour cells more sensitive to the radiation. The combination of IMRT and concurrent cisplatin achieves local control rates of 85–90% for T3N1 NPC at five years. That is the standard we are aiming for.

Stage 2 — Left Hemithyroidectomy with Central Neck Dissection

Timing: Three months after completion of NPC chemoradiotherapy; patient recovered well; acute radiation effects resolved; thyroid function and general condition confirmed suitable for surgery.

Anaesthesia and positioning: General anaesthesia with intraoperative neuromonitoring (IONM) of the recurrent laryngeal nerve — standard of care for thyroid surgery to prevent inadvertent nerve injury. Supine position with neck extended.

Hemithyroidectomy: Collar incision; platysma divided; strap muscles retracted. Left thyroid lobe and isthmus mobilised; recurrent laryngeal nerve identified and preserved under continuous IONM; superior and inferior parathyroid glands on the left identified and preserved with their vascular supply. Left thyroid lobe and isthmus divided and removed. Specimen sent for intraoperative frozen section — confirmed papillary thyroid carcinoma.

Central neck dissection: Left central compartment (level VI) lymph node dissection performed — removing the pre-tracheal, paratracheal, and prelaryngeal lymph nodes. Specimen submitted for permanent histopathology.

Operative data: Total operative time approximately 90 minutes; intraoperative blood loss approximately 50 mL; no intraoperative complications; recurrent laryngeal nerve signal maintained throughout on IONM.

Final histopathology: Papillary thyroid carcinoma confirmed; all resection margins clear; central neck dissection — 0 of 6 lymph nodes positive for metastasis; no lymphovascular invasion; no extrathyroidal extension.

Post-operative TSH suppression: Levothyroxine initiated post-operatively; dose titrated to maintain TSH below 0.1 mU/L — the target for intermediate-risk PTC to suppress TSH-driven tumour growth.

Post-treatment Management and Outcomes

NPC Response Assessment

• 3 months post-chemoradiotherapy — nasopharyngeal enhanced MRI: Near-complete response of the nasopharyngeal primary tumour and cervical nodal metastases; residual soft tissue changes consistent with post-radiation fibrosis rather than active tumour; blood-tinged nasal discharge resolved completely
• Ongoing surveillance: Nasopharyngeal MRI and EBV DNA monitoring at regular intervals; no evidence of locoregional recurrence or distant metastasis at three-year follow-up

Thyroid Cancer Outcomes

• Post-operative recovery: No hoarseness, no hypocalcaemia, no wound complications; discharged on post-operative day 2
• 1-month thyroid ultrasound: No residual thyroid tissue or suspicious nodules in the operative bed
• TSH suppression: TSH maintained below 0.1 mU/L on levothyroxine; thyroglobulin undetectable — consistent with complete surgical resection
• 3-year follow-up: No evidence of thyroid cancer recurrence on ultrasound or thyroglobulin monitoring; no NPC recurrence on nasopharyngeal MRI or EBV DNA; patient in good health with excellent quality of life

Expert Commentary — Dr. Guo Liang

1. Synchronous Multiple Primary Malignancies: Why Systematic Evaluation Is Non-Negotiable

The incidence of synchronous multiple primary malignancies — two or more independent primary cancers diagnosed simultaneously or within six months — is higher than most clinicians appreciate. In head and neck oncology, the field cancerisation hypothesis — the concept that carcinogenic exposure affects the entire mucosal field of the upper aerodigestive tract, not just the site of the clinically apparent tumour — explains the elevated risk of synchronous primaries in the oral cavity, pharynx, larynx, and oesophagus. But the thyroid is not part of the mucosal field, and thyroid cancer is common enough in the general population — particularly papillary microcarcinoma — that its co-occurrence with NPC in this patient may reflect independent carcinogenesis rather than a shared aetiology. The clinical lesson is the same regardless of mechanism: every patient presenting with a head and neck malignancy requires systematic ultrasound evaluation of the thyroid, because the thyroid is in the surgical and radiotherapy field, because thyroid cancer is common, and because a missed synchronous thyroid primary will be irradiated during NPC treatment — potentially complicating subsequent thyroid surgery with radiation-induced fibrosis and vascular changes.

2. IMRT for Nasopharyngeal Carcinoma: Precision Dose Delivery in a Complex Anatomical Region

The nasopharynx is surrounded by critical structures — the brainstem, spinal cord, optic chiasm, temporal lobes, parotid glands, and temporomandibular joints — that limit the dose that can be safely delivered with conventional radiotherapy techniques. IMRT resolves this constraint by modulating the intensity of multiple radiation beams to create a dose distribution that conforms tightly to the target volume while creating steep dose gradients at the boundaries of adjacent critical structures. For NPC, IMRT achieves two goals simultaneously: delivery of tumoricidal doses (70 Gy) to the primary tumour and involved nodes, and preservation of parotid gland function by constraining the mean parotid dose below 26 Gy. The clinical consequence of parotid preservation is the prevention of permanent xerostomia — the most debilitating long-term toxicity of conventional NPC radiotherapy, which impairs swallowing, speech, dental health, and quality of life for decades. At Fudan University Shanghai Cancer Center, IMRT is the standard technique for all NPC cases, and parotid mean dose constraints are treated as mandatory rather than aspirational planning objectives.

3. Sequencing Surgery and Radiotherapy in the Irradiated Neck: Why Timing Matters

Operating in a previously irradiated field is one of the most technically demanding challenges in head and neck surgery. Radiation causes progressive fibrosis, obliterative endarteritis, and impaired wound healing in the irradiated tissues — changes that increase the risk of wound dehiscence, fistula formation, carotid artery exposure, and hypoparathyroidism when surgery is performed in the irradiated neck. The risk is highest in the first three to six months after radiotherapy, when acute radiation effects are resolving and the fibrotic response is at its most active. Deferring thyroid surgery until three months after NPC chemoradiotherapy — as in this case — allows the acute mucosal and soft tissue reactions to resolve while avoiding the period of maximum fibrotic activity. The three-month interval also allows the patient to recover nutritional status, immune function, and physiological reserve after the metabolic demands of six weeks of concurrent chemoradiotherapy. The thyroid cancer, at cT1aN0M0, has a prognosis so favourable that a three-month deferral carries no meaningful oncological cost — but operating three months earlier, in the acutely irradiated neck, would carry a substantially higher surgical complication rate.

4. TSH Suppression After Thyroid Cancer Surgery: Hormonal Oncology in Practice

Papillary thyroid carcinoma cells express TSH receptors and are stimulated to proliferate by TSH — the pituitary hormone that drives normal thyroid cell growth. Post-operative TSH suppression with supraphysiological doses of levothyroxine reduces the TSH-driven proliferative stimulus on any residual thyroid cancer cells, reducing the risk of recurrence. The target TSH level is risk-stratified: for low-risk PTC (T1a, clear margins, no nodal metastasis), TSH suppression to 0.5–2.0 mU/L is acceptable; for intermediate-risk PTC, suppression to below 0.1 mU/L is recommended. In this patient, the concurrent NPC — a separate malignancy requiring its own surveillance — and the clear surgical margins and negative central nodes place him in the intermediate-risk category for TSH suppression, given the complexity of his oncological history. The levothyroxine dose is titrated at each follow-up visit based on TSH measurement, with the goal of maintaining suppression without inducing atrial fibrillation or accelerated bone loss — the principal adverse effects of chronic TSH suppression in older patients.

How CMCS Shanghai Coordinated This Case

CMCS Shanghai supported Mr. Morrison and his family from initial presentation through three-year follow-up, including: urgent coordination of head and neck surgery consultation with Dr. Guo Liang at Fudan University Shanghai Cancer Center with priority appointment scheduling; bilingual review of all prior imaging and laboratory records with clinical summary for the MDT; coordination of nasopharyngoscopy and endoscopy-guided biopsy with bilingual pathology report translation and staging interpretation; coordination of enhanced CT of the neck and nasopharynx with bilingual radiology report translation; coordination of thyroid ultrasound and ultrasound-guided FNAB with bilingual cytology report translation and TIRADS classification explanation; coordination of distant metastasis workup including bone scan, chest CT, and abdominal ultrasound with bilingual results communication; bilingual interpretation throughout all MDT discussions involving head and neck surgery, medical oncology, radiation oncology, and radiology; IMRT treatment coordination including CT simulation scheduling, mask fitting appointment, and bilingual explanation of the radiotherapy planning process and daily treatment schedule; concurrent cisplatin chemotherapy coordination including pre-medication protocol, hydration scheduling, and bilingual antiemetic instructions; acute toxicity management support including oral mucositis care protocol in English and bilingual liaison with the nursing team; real-time updates to the patient's wife and his oncologist in Sydney throughout the six-week chemoradiotherapy course; three-month post-chemoradiotherapy MRI coordination with bilingual response assessment communication; thyroid surgery coordination including pre-operative workup, intraoperative neuromonitoring consent, and bilingual surgical consent support; post-operative recovery coordination including calcium monitoring, levothyroxine initiation, and bilingual discharge instructions; TSH suppression monitoring coordination with regular thyroid function testing and dose adjustment communication; three-year surveillance coordination including nasopharyngeal MRI, EBV DNA monitoring, thyroid ultrasound, and thyroglobulin measurement with results communicated to the patient's oncologist and GP in Australia; and establishment of a dual-tumour surveillance protocol integrating NPC and thyroid cancer follow-up into a unified annual assessment schedule.

For international patients with nasopharyngeal carcinoma, thyroid cancer, or complex synchronous head and neck malignancies requiring multidisciplinary oncological treatment in Shanghai, Dr. Guo Liang's team at Fudan University Shanghai Cancer Center represents head and neck oncology expertise at the international frontier — combining IMRT-based chemoradiotherapy, precision thyroid surgery, and structured long-term dual-tumour surveillance to achieve locoregional control and surgical cure in patients with multiple concurrent primary malignancies. CMCS ensures that expertise is accessible: in the patient's language, with overseas oncologists and families informed at every step, from the first nasopharyngoscopy through three-year remission surveillance.

This case report is de-identified and published for educational purposes. All clinical details have been anonymized in accordance with patient privacy standards. CMCS Shanghai is a medical concierge service and does not provide direct medical care.